Candel Therapeutics (CADL) Non-Current Assets (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Non-Current Assets data on file, last reported at $3.8 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Assets rose 24.3% year-over-year to $3.8 million; the trailing twelve-month figure through Dec 2025 stood at $12.4 million (down 13.53% YoY), and the FY2025 full-year result was $3.8 million, up 24.3% from the prior year.
• Non-Current Assets advanced to $3.8 million in Q4 2025, from $3.5 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $6.3 million in Q2 2021 to a low of $2.4 million in Q2 2025.
• A 5-year average of $4.5 million and a median of $4.4 million in 2023 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets jumped 35.84% in 2021 and slumped 37.07% in 2025, its largest moves.
• Tracing CADL's Non-Current Assets over 5 years: stood at $4.3 million in 2021, then soared by 34.88% to $5.7 million in 2022, then dropped by 23.36% to $4.4 million in 2023, then tumbled by 30.47% to $3.1 million in 2024, then rose by 24.3% to $3.8 million in 2025.
• Business Quant data shows CADL's Non-Current Assets at $3.8 million in Q4 2025, $3.5 million in Q3 2025, and $2.4 million in Q2 2025.